Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis

Frontiers in Microbiology
Azin KhafipourJean-Eric Ghia

Abstract

The pro-inflammatory mediator receptor activator of nuclear factor-kappa B ligand (RANKL) plays a significant role in the development of rheumatoid arthritis; however, its role in inflammatory bowel disease is unknown. Genome-wide association meta-analysis for Crohn's disease (CD) identified a variant near the TNFSF11 gene that encodes RANKL and CD risk allele increased expression of RANKL in specific cell lines. This study aims to elucidate if the RANKL inhibitor denosumab can reduce the severity of experimental colitis and modify the gut microbiota composition using murine dinitrobenzenesulfonic acid (DNBS)-experimental model of colitis mimicking CD. In colitic conditions, denosumab treatment significantly decreased the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α within the colonic mucosa. Moreover, colitis was accompanied by disruption of gut microbiota, and preventative treatment with denosumab modulated this disruption. Denosumab treatment also modified the alpha- and beta diversity of colonic mucosa and fecal microbiota. These results provide a rationale for considering denosumab as a future potential therapy in CD; however, more detailed experimental and clinical studies are warranted.

References

Oct 16, 2002·Infection and Immunity·W I KhanS M Collins
Jul 8, 2005·Journal of Clinical Microbiology·Alexander SwidsinskiHerbert Lochs
Jul 6, 2006·Applied and Environmental Microbiology·T Z DeSantisG L Andersen
Sep 22, 2006·Journal of Clinical Microbiology·Uri GophnaSander J O Veldhuyzen van Zanten
Jan 31, 2007·Inflammatory Bowel Diseases·Shadi SepehriDenis O Krause
Jun 26, 2007·Applied and Environmental Microbiology·Qiong WangJames R Cole
Oct 9, 2007·Joint, Bone, Spine : Revue Du Rhumatisme·Anne Fouque-Aubert, Roland Chapurlat
Nov 20, 2008·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Paul J KostenuikJohn K Sullivan
Dec 23, 2008·Immunity·Lauren A ZenewiczRichard A Flavell
Mar 11, 2009·Gastroenterology·Jean-Eric GhiaStephen M Collins
May 1, 2009·Arthritis and Rheumatism·Lorenz C HofbauerReinhold G Erben
Jun 19, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·A D AnastasilakisE Terpos
Sep 29, 2009·Applied and Environmental Microbiology·Ehsan KhafipourDenis O Krause
Mar 13, 2010·PloS One·Morgan N PriceAdam P Arkin
Apr 13, 2010·Nature Methods·J Gregory CaporasoRob Knight
Aug 17, 2010·Bioinformatics·Robert C Edgar
Jun 28, 2011·Bioinformatics·Robert C EdgarRob Knight
Jun 28, 2011·Genome Biology·Nicola SegataCurtis Huttenhower
Feb 16, 2012·BMC Bioinformatics·Andre P MasellaJosh D Neufeld
Aug 8, 2012·Therapeutic Advances in Musculoskeletal Disease·Paul D Miller
Jan 10, 2013·Current Medical Research and Opinion·Robert JosseMarla Shapiro
May 1, 2013·Immunology and Cell Biology·Eva A V MoelantsPaul Proost
Aug 27, 2013·Nature Biotechnology·Morgan G I LangilleCurtis Huttenhower
Oct 10, 2013·Inflammatory Bowel Diseases·Brigitta M BrinkmanPeter Vandenabeele
Jun 8, 2014·Inflammopharmacology·Nidhi GoyalPuneet Kumar

❮ Previous
Next ❯

Datasets Mentioned

BETA
SRR1158862

Methods Mentioned

BETA
enzyme-linked immunosorbent assays
Reverse Transcription Polymerase Chain Reaction
electrophoresis
PCR
Illumina sequencing

Software Mentioned

UCHIME
LEfSe
Greengenes
QIIME
BLAST
PANDAseq assembler
PERMANOVA
R vegan
corrplot
FastTree

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Related Papers

Nature Reviews. Drug Discovery
René RizzoliPeter Kirkpatrick
British Journal of Clinical Pharmacology
Eline A DuboisAdam F Cohen
Current Osteoporosis Reports
Jameel IqbalMone Zaidi
Current Opinion in Supportive and Palliative Care
Allan Lipton, Ira Jacobs
© 2021 Meta ULC. All rights reserved